You are here

A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hepatocellular Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of locally advanced or metastatic liver cancer obtained by
histology/cytology or by imaging

- Documented progression on or after treatment with sorafenib, confirmed by the
Investigator upon review of appropriate imaging documentation

- Child Pugh Class A disease

- ECOG [Eastern Cooperative Oncology Group] Performance Status (PS) 0 or 1

- Mandatory tumor biopsy at study entry (pre-randomization, unless already collected
after sorafenib progression but within 3 months of enrollment and no systemic
anticancer therapies received)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Prior systemic treatment for advanced liver cancer other than sorafenib-including
therapy

- Prior local therapy within 2 weeks of starting the study treatment

- Presence of main portal vein invasion by liver cancer

NCT01911273
Pfizer
Terminated
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now